Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Meta Expands AI Training With Employee Activity Tracking Tools 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
- Cowen and Company 36th Annual Health Care Conference on March 8 in Boston
- Raymond James 37th Annual Institutional Investors Conference on March 9 in Orlando
- Barclays Global Healthcare Conference on March 16 in Miami
SAN RAFAEL, Calif., March 03, 2016 -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the Cowen and Company 36th Annual Health Care Conference on March 8, 2016 at 8:40am ET in Boston. Management will also participate in the Raymond James 37th Annual Institutional Investors Conference on March 9, 2016 in Orlando and the Barclays Global Healthcare Conference on March 16, 2016 in Miami. To access the live webcasts, please visit the investor section of the BioMarin website, www.BMRN.com. A replay will also be archived on the site for at least one week following the event.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.BMRN.com.
Contacts: Investors Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451
